D

Deciphera Pharmaceuticals Inc
F:D05

Watchlist Manager
Deciphera Pharmaceuticals Inc
F:D05
Watchlist
Price: 42.4 EUR 1.68% Market Closed
Market Cap: 3.5B EUR
Have any thoughts about
Deciphera Pharmaceuticals Inc?
Write Note

Intrinsic Value

D05's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one D05 stock under the Base Case scenario is 13.51 EUR. Compared to the current market price of 42.4 EUR, Deciphera Pharmaceuticals Inc is Overvalued by 68%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

D05 Intrinsic Value
13.51 EUR
Overvaluation 68%
Intrinsic Value
Price
D
Worst Case
Base Case
Best Case

Valuation Backtest
Deciphera Pharmaceuticals Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for D05 cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about D05?
Bearish
Neutral
Bullish
Discover Undervalued Stocks
Biotechnology Industry

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Deciphera Pharmaceuticals Inc

Provide an overview of the primary business activities
of Deciphera Pharmaceuticals Inc.

What unique competitive advantages
does Deciphera Pharmaceuticals Inc hold over its rivals?

What risks and challenges
does Deciphera Pharmaceuticals Inc face in the near future?

Summarize the latest earnings call
of Deciphera Pharmaceuticals Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Deciphera Pharmaceuticals Inc.

Provide P/S
for Deciphera Pharmaceuticals Inc.

Provide P/E
for Deciphera Pharmaceuticals Inc.

Provide P/OCF
for Deciphera Pharmaceuticals Inc.

Provide P/FCFE
for Deciphera Pharmaceuticals Inc.

Provide P/B
for Deciphera Pharmaceuticals Inc.

Provide EV/S
for Deciphera Pharmaceuticals Inc.

Provide EV/GP
for Deciphera Pharmaceuticals Inc.

Provide EV/EBITDA
for Deciphera Pharmaceuticals Inc.

Provide EV/EBIT
for Deciphera Pharmaceuticals Inc.

Provide EV/OCF
for Deciphera Pharmaceuticals Inc.

Provide EV/FCFF
for Deciphera Pharmaceuticals Inc.

Provide EV/IC
for Deciphera Pharmaceuticals Inc.

Show me price targets
for Deciphera Pharmaceuticals Inc made by professional analysts.

What are the Revenue projections
for Deciphera Pharmaceuticals Inc?

How accurate were the past Revenue estimates
for Deciphera Pharmaceuticals Inc?

What are the Net Income projections
for Deciphera Pharmaceuticals Inc?

How accurate were the past Net Income estimates
for Deciphera Pharmaceuticals Inc?

What are the EPS projections
for Deciphera Pharmaceuticals Inc?

How accurate were the past EPS estimates
for Deciphera Pharmaceuticals Inc?

What are the EBIT projections
for Deciphera Pharmaceuticals Inc?

How accurate were the past EBIT estimates
for Deciphera Pharmaceuticals Inc?

Compare the revenue forecasts
for Deciphera Pharmaceuticals Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Deciphera Pharmaceuticals Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Deciphera Pharmaceuticals Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Deciphera Pharmaceuticals Inc compared to its peers.

Compare the P/E ratios
of Deciphera Pharmaceuticals Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Deciphera Pharmaceuticals Inc with its peers.

Analyze the financial leverage
of Deciphera Pharmaceuticals Inc compared to its main competitors.

Show all profitability ratios
for Deciphera Pharmaceuticals Inc.

Provide ROE
for Deciphera Pharmaceuticals Inc.

Provide ROA
for Deciphera Pharmaceuticals Inc.

Provide ROIC
for Deciphera Pharmaceuticals Inc.

Provide ROCE
for Deciphera Pharmaceuticals Inc.

Provide Gross Margin
for Deciphera Pharmaceuticals Inc.

Provide Operating Margin
for Deciphera Pharmaceuticals Inc.

Provide Net Margin
for Deciphera Pharmaceuticals Inc.

Provide FCF Margin
for Deciphera Pharmaceuticals Inc.

Show all solvency ratios
for Deciphera Pharmaceuticals Inc.

Provide D/E Ratio
for Deciphera Pharmaceuticals Inc.

Provide D/A Ratio
for Deciphera Pharmaceuticals Inc.

Provide Interest Coverage Ratio
for Deciphera Pharmaceuticals Inc.

Provide Altman Z-Score Ratio
for Deciphera Pharmaceuticals Inc.

Provide Quick Ratio
for Deciphera Pharmaceuticals Inc.

Provide Current Ratio
for Deciphera Pharmaceuticals Inc.

Provide Cash Ratio
for Deciphera Pharmaceuticals Inc.

What is the historical Revenue growth
over the last 5 years for Deciphera Pharmaceuticals Inc?

What is the historical Net Income growth
over the last 5 years for Deciphera Pharmaceuticals Inc?

What is the current Free Cash Flow
of Deciphera Pharmaceuticals Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Deciphera Pharmaceuticals Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Deciphera Pharmaceuticals Inc

Current Assets 349.9m
Cash & Short-Term Investments 272.5m
Receivables 32.7m
Other Current Assets 44.7m
Non-Current Assets 71m
Long-Term Investments 26.8m
PP&E 36.1m
Other Non-Current Assets 8.1m
Current Liabilities 83.4m
Accounts Payable 19.5m
Accrued Liabilities 34.7m
Other Current Liabilities 29.3m
Non-Current Liabilities 21.4m
Other Non-Current Liabilities 21.4m
Efficiency

Earnings Waterfall
Deciphera Pharmaceuticals Inc

Revenue
174.9m USD
Cost of Revenue
-5.3m USD
Gross Profit
169.6m USD
Operating Expenses
-376.1m USD
Operating Income
-206.5m USD
Other Expenses
16.1m USD
Net Income
-190.4m USD

Free Cash Flow Analysis
Deciphera Pharmaceuticals Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

In 2023, QINLOCK's U.S. net product revenue reached $121.5 million, reflecting a 25% rise with solid demand. The Q4 revenue surged by 38% from the previous year's Q4 to $35.3 million. Anticipated continued growth in 2024 is underpinned by QINLOCK's standard of care status in fourth-line GIST, with gross to net estimates and Patient Assistance Program use remaining consistent. Internationally, QINLOCK gained traction, especially in Europe with a 56% Q4 revenue jump and expansion plans unfolding across Central and Eastern Europe, priming the international revenue for further growth. The U.S. market for TGCT is valued around $700 million, with Deciphera well-placed to grasp this opportunity. To broaden its therapeutic horizon, a Phase II study on vimseltinib for GVHD is set to start by year's end.

What is Earnings Call?
Fundamental Scores

D05 Profitability Score
Profitability Due Diligence

Deciphera Pharmaceuticals Inc's profitability score is 30/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional 3-Years Revenue Growth
ROIC is Increasing
Exceptional 1-Year Revenue Growth
30/100
Profitability
Score

Deciphera Pharmaceuticals Inc's profitability score is 30/100. The higher the profitability score, the more profitable the company is.

D05 Solvency Score
Solvency Due Diligence

Deciphera Pharmaceuticals Inc's solvency score is 63/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Low D/E
Low Altman Z-Score
63/100
Solvency
Score

Deciphera Pharmaceuticals Inc's solvency score is 63/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

D05 Price Targets Summary
Deciphera Pharmaceuticals Inc

There are no price targets for D05.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for D05?

Click here to dive deeper.

Dividends

Deciphera Pharmaceuticals Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for D05 is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Deciphera Pharmaceuticals Inc

Country

United States of America

Industry

Biotechnology

Market Cap

3.5B EUR

Dividend Yield

0%

Description

Deciphera Pharmaceuticals, Inc. engages in discovering, developing, and delivering important new medicines to patients for the treatment of cancer. The company is headquartered in Waltham, Massachusetts and currently employs 280 full-time employees. The company went IPO on 2017-09-28. The firm has developed a switch-control kinase inhibitor platform in kinase biology to execute its strategy to develop a portfolio of medicines. The firm's QINLOCK, is a switch-control kinase inhibitor, engineered using its drug discovery platform and developed for the treatment of fourth-line gastrointestinal stromal tumor (GIST). The company has two additional clinical-stage assets, vimseltinib and DCC-3116. Vimseltinib is an investigational, orally administered, potent, and highly selective switch-control kinase inhibitor of the colony stimulating factor 1 receptor (CSF1R). Vimseltinib is in a pivotal phase III study in patients with tenosynovial giant cell tumor (TGCT). DCC-3116 is an investigational, orally administered, potent, and highly selective switch-control inhibitor of the ULK kinase.

Contact

MASSACHUSETTS
Waltham
200 Smith St
+17812096400.0
www.deciphera.com

IPO

2017-09-28

Employees

280

Officers

President, CEO & Director
Mr. Steven L. Hoerter
Executive VP, CFO & Treasurer
Mr. Thomas Patrick Kelly J.D.
Executive VP & Chief Scientific Officer
Dr. Dashyant Dhanak Ph.D.
Senior VP & Chief Commercial Officer
Mr. Daniel C. Martin
Executive VP & Chief Medical Officer
Dr. Matthew L. Sherman M.D.
Senior VP & Chief Technical Officer
Dr. Kevin Brodbeck Ph.D.
Show More
Senior Vice President of Finance & Investor Relations
Jennifer Larson
Senior VP & General Counsel
Mr. Jeffrey M. Held J.D.
Senior VP & Chief Human Resources Officer
Ms. Lisa Amaya Price
Senior VP & Chief Development Officer
Ms. Jama Pitman
Show Less

See Also

Discover More
What is the Intrinsic Value of one D05 stock?

The intrinsic value of one D05 stock under the Base Case scenario is 13.51 EUR.

Is D05 stock undervalued or overvalued?

Compared to the current market price of 42.4 EUR, Deciphera Pharmaceuticals Inc is Overvalued by 68%.

Back to Top